You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The agency cleared two Roche tests that run on its Cobas systems. One does Chlamydia trachomatis and Neisseria gonorrhoeae testing and the other does hematology testing.
The firm is in the midst of evaluating its strategic options and has hired Raymond James to assist in the process, which could include the sale of the firm, it said.
The companies will join their respective technologies into a precision oncology testing and analysis offering.
Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.
Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.
The program enables NJ-based tech firms to sell net operating losses and R&D tax credits for at least 80 percent of the value of the tax benefits.
The test, which also is FDA-approved, can be used to identify best responders to three non-small cell lung cancer treatment regimens.
The company plans to offer 3.5 million units, comprising one share of common stock and one warrant to buy an additional share, at $2 per unit.
The revenue increase was primarily driven by increased revenue in the company's biopharma services, clinical services, and discovery services divisions.
The firm missed analysts' expectations on both the top and bottom lines, despite a reported 20 percent increase in clinical services revenues during the quarter.